Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat RevDrug Discov. 2017;16(12):843–62.

Article  CAS  Google Scholar 

Lin CM, Cooles FA, Isaacs JD. Basic Mechanisms of JAK Inhibition. Med J Rheumatol. 2020;31(Suppl 1):100.

Google Scholar 

Toth L, Juhasz MF, Szabo L, et al. Janus kinase inhibitors improve disease activity and patient-reported outcomes in rheumatoid arthritis: a systematic review and meta-analysis of 24,135 patients. Int J Mol Sci 2022;23(3).

Harkins P, Burke E, Swales C, Silman A, Conway R. Are Janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis? A systematic review and meta-analysis. Int J Rheum Dis 2023;26(1)31–42. https://doi.org/10.1111/1756-185X.14447.

Lee YH. Comparative efficacy and safety of janus kinase inhibitors and secukinumab in patients with active ankylosing spondylitis: a systematic review and meta-analysis. Pharmacology 2022:1–8.

Li S, Li F, Mao N, Wang J, Xie X. Efficacy and safety of Janus kinase inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis. Eur J Intern Med. 2022;102:47–53.

Article  CAS  PubMed  Google Scholar 

XELJANZ (tofacitinib). https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203214s028,208246s013,213082s003lbl.pdf. In. Silver Spring, MD: U.S. Food and Drug Administration; 2021.

RINVOQ®(upadacitinib). https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211675s002s005lbl.pdf. In. Silver Spring, MD: U.S. Food and Drug Administration; 2021.

OLUMIANT (baricitinib). https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207924s004lbl.pdf. In. Silver Spring, MD: U.S. Food and Drug Administration; 2021.

Mannion ML, Cron RQ. Therapeutic strategies for treating juvenile idiopathic arthritis. Curr Opin Pharmacol. 2022;64: 102226.

Article  CAS  PubMed  Google Scholar 

Ruperto N, Martini A. Current and future perspectives in the management of juvenile idiopathic arthritis. Lancet Child Adolesc Health. 2018;2(5):360–70.

Article  PubMed  Google Scholar 

Chen J, Cheng J, Yang H, et al. The efficacy and safety of Janus kinase inhibitors in patients with atopic dermatitis: a systematic review and meta-analysis. J Am Acad Dermatol. 2022;87(2):495–6.

Article  CAS  PubMed  Google Scholar 

Li C, Sun X, Zhao K, et al. Efficacy and safety of janus kinase inhibitors for the treatment of atopic dermatitis: a systematic review and meta-analysis. Dermatology. 2022;238(4):725–35.

Article  CAS  PubMed  Google Scholar 

Ma C, Lee JK, Mitra AR, et al. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther. 2019;50(1):5–23.

Article  PubMed  Google Scholar 

Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108–23.

Article  PubMed  Google Scholar 

Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–62.

Article  CAS  PubMed  Google Scholar 

Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.

Article  PubMed  Google Scholar 

Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–99.

Article  CAS  PubMed  Google Scholar 

Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316–26.

Article  CAS  PubMed  Google Scholar 

Updated recommendations to minimise the risks of malignancy, major adverse cardiovascular events, serious infections, venous thromboembolism and mortality with use of Janus kinase inhibitors (JAKi). https://www.ema.europa.eu/en/medicines/dhpc/updated-recommendations-minimise-risks-malignancy-major-adverse-cardiovascular-events-serious#documents-section. In. The Netherlands: European Medicine Agency; 2023.

Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287–93.

Article  PubMed  Google Scholar 

Mehta B, Pedro S, Ozen G, et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open. 2019;5(1): e000935.

Article  PubMed  PubMed Central  Google Scholar 

Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2294–300.

Article  PubMed  Google Scholar 

Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology. 2013;52(1):53–61.

Article  CAS  PubMed  Google Scholar 

Yun H, Xie F, Delzell E, et al. Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. Ann Rheum Dis. 2015;74(6):1065–71.

Article  CAS  PubMed  Google Scholar 

Yun H, Xie F, Delzell E, et al. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare. Arthritis Rheumatol. 2016;68(1):56–66.

Article  CAS  PubMed  Google Scholar 

Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386(9990):258–65.

Article  PubMed  PubMed Central  Google Scholar 

Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011(2):CD008794.

Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology. 2019;58(10):1755–66.

Article  CAS  PubMed  Google Scholar 

Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology 2020;158(6):1554–73 e12.

Sepriano A, Kerschbaumer A, Smolen JS, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020;79(6):760–70.

Article  CAS  PubMed  Google Scholar 

Galloway JB, Mercer LK, Moseley A, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2013;72(2):229–34.

Article  CAS  PubMed  Google Scholar 

Gialouri CG, Moustafa S, Thomas K, Hadziyannis E, Vassilopoulos D. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies. Rheumatol Int. 2023;43(3):421–35. https://doi.org/10.1007/s00296-022-05270-6.

Song Y-J, Cho S-K, Kim H, et al. Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested case–control study. RMD Open. 2022;8(1): e001892.

Article  PubMed  PubMed Central  Google Scholar 

Cohen SB, Van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2021;80(3):304–11.

Article  CAS  PubMed  Google Scholar 

Wang F, Sun L, Wang S, et al. Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. Mayo Clin Proc. 2020;95(7):1404–19.

Article  CAS  PubMed  Google Scholar 

Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39–52.

Article  CAS  PubMed  Google Scholar 

Cantini F, Blandizzi C, Niccoli L, Petrone L, Goletti D. Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. Expert Opin Drug Saf. 2020;19(7):861–72.

Article  CAS  PubMed  Google Scholar 

Holmqvist ME, Neovius M, Eriksson J, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA. 2012;308(13):1350.

Article  CAS  PubMed  Google Scholar 

Ogdie A, Kay McGill N, Shin DB, et al. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. Eur Heart J. 2018;39(39):3608–14.

Article  PubMed  Google Scholar 

Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med. 2011;9(1):1.

Article  PubMed  PubMed Central  Google Scholar 

Bilal J, Riaz IB, Naqvi SAA, et al. Janus kinase inhibitors and risk of venous thromboembolism: a systematic review and meta-analysis. Mayo Clin Proc. 2021;96(7):1861–73.

Article  CAS  PubMed  Google Scholar 

Maqsood MH, Weber BN, Haberman RH, Lo Sicco KI, Bangalore S, Garshick MS. Cardiovascular and venous thromboembolic risk with janus kinase inhibitors in immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized trials. ACR Open Rheumatol. 2022;4(10):912–22.

Article  PubMed  PubMed Central  Google Scholar 

Chen TL, Lee LL, Huang HK, Chen LY, Loh CH, Chi CC. Association of risk of incident venous thromboembolism with atopic dermatitis and treatment with janus kinase inhibitors: a systematic review and meta-analysis. JAMA Dermatol. 2022;158(11):1254–61.

Article  PubMed  Google Scholar 

Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2019;78(8):1048–54.